BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29967263)

  • 21. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
    Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M
    Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of the local immune status between the primary and metastatic tumor in colorectal cancer: a retrospective study.
    Shibutani M; Maeda K; Nagahara H; Fukuoka T; Matsutani S; Kashiwagi S; Tanaka H; Hirakawa K; Ohira M
    BMC Cancer; 2018 Apr; 18(1):371. PubMed ID: 29614981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liver specific gene immunotherapies resolve immune suppressive ectopic lymphoid structures of liver metastases and prolong survival.
    Goodwin TJ; Shen L; Hu M; Li J; Feng R; Dorosheva O; Liu R; Huang L
    Biomaterials; 2017 Oct; 141():260-271. PubMed ID: 28700955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy.
    Wang HB; Yao H; Li CS; Liang LX; Zhang Y; Chen YX; Fang JY; Xu J
    J Dig Dis; 2017 Oct; 18(10):574-581. PubMed ID: 28851046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Looking back 2018--focused on colorectal cancer].
    Cai J; Wang L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):9-16. PubMed ID: 30703787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with metastatic colorectal cancer.
    Shibutani M; Maeda K; Nagahara H; Ohtani H; Sakurai K; Yamazoe S; Kimura K; Toyokawa T; Amano R; Tanaka H; Muguruma K; Hirakawa K
    World J Gastroenterol; 2015 Sep; 21(34):9966-73. PubMed ID: 26379401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adoptive cellular therapy of human breast and colorectal tumor targets using ex vivo activated memory T lymphocytes with potentiation by cis-diamminedichloroplatinum(II).
    Gold JE; Bleiweiss IJ; Goldfarb AB; Bauer JJ; Gelernt IM; Schwartz ME; Reiner MA; Miller CM; Weiss MF; Brower ST
    J Surg Oncol; 1994 Apr; 55(4):222-8. PubMed ID: 8159004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy in colorectal cancer: What have we learned so far?
    Sanchez-Castañón M; Er TK; Bujanda L; Herreros-Villanueva M
    Clin Chim Acta; 2016 Sep; 460():78-87. PubMed ID: 27350293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen.
    Limagne E; Euvrard R; Thibaudin M; Rébé C; Derangère V; Chevriaux A; Boidot R; Végran F; Bonnefoy N; Vincent J; Bengrine-Lefevre L; Ladoire S; Delmas D; Apetoh L; Ghiringhelli F
    Cancer Res; 2016 Sep; 76(18):5241-52. PubMed ID: 27496709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy.
    Chesney JA; Mitchell RA; Yaddanapudi K
    J Leukoc Biol; 2017 Sep; 102(3):727-740. PubMed ID: 28546500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolyl Hydroxylase 3 Attenuates MCL-1-Mediated ATP Production to Suppress the Metastatic Potential of Colorectal Cancer Cells.
    Radhakrishnan P; Ruh N; Harnoss JM; Kiss J; Mollenhauer M; Scherr AL; Platzer LK; Schmidt T; Podar K; Opferman JT; Weitz J; Schulze-Bergkamen H; Koehler BC; Ulrich A; Schneider M
    Cancer Res; 2016 Apr; 76(8):2219-30. PubMed ID: 26921340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of SMAD4 Promotes Lung Metastasis of Colorectal Cancer by Accumulation of CCR1+ Tumor-Associated Neutrophils through CCL15-CCR1 Axis.
    Yamamoto T; Kawada K; Itatani Y; Inamoto S; Okamura R; Iwamoto M; Miyamoto E; Chen-Yoshikawa TF; Hirai H; Hasegawa S; Date H; Taketo MM; Sakai Y
    Clin Cancer Res; 2017 Feb; 23(3):833-844. PubMed ID: 27492974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Versican-Derived Matrikines Regulate Batf3-Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer.
    Hope C; Emmerich PB; Papadas A; Pagenkopf A; Matkowskyj KA; Van De Hey DR; Payne SN; Clipson L; Callander NS; Hematti P; Miyamoto S; Johnson MG; Deming DA; Asimakopoulos F
    J Immunol; 2017 Sep; 199(5):1933-1941. PubMed ID: 28754680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishment and characterization of cell lines from chromosomal instable colorectal cancer.
    Maletzki C; Gock M; Randow M; Klar E; Huehns M; Prall F; Linnebacher M
    World J Gastroenterol; 2015 Jan; 21(1):164-76. PubMed ID: 25574089
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
    Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
    Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical assessment and identification of immuno-oncology markers concerning the 19-gene based risk classifier in stage IV colorectal cancer.
    Lee JL; Roh SA; Kim CW; Kwon YH; Ha YJ; Kim SK; Kim SY; Cho DH; Kim YS; Kim JC
    World J Gastroenterol; 2019 Mar; 25(11):1341-1354. PubMed ID: 30918427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.
    Veluchamy JP; Spanholtz J; Tordoir M; Thijssen VL; Heideman DA; Verheul HM; de Gruijl TD; van der Vliet HJ
    PLoS One; 2016; 11(6):e0157830. PubMed ID: 27314237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients.
    Tada K; Kitano S; Shoji H; Nishimura T; Shimada Y; Nagashima K; Aoki K; Hiraoka N; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Yamada Y; Katayama N; Boku N; Heike Y; Hamaguchi T
    Cancer Immunol Res; 2016 Jul; 4(7):592-9. PubMed ID: 27197061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natural killer cells infiltrating colorectal cancer and MHC class I expression.
    Sandel MH; Speetjens FM; Menon AG; Albertsson PA; Basse PH; Hokland M; Nagelkerke JF; Tollenaar RA; van de Velde CJ; Kuppen PJ
    Mol Immunol; 2005 Feb; 42(4):541-6. PubMed ID: 15607811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.